Douglas Ross-Thriepland, BSc PhD

AstraZeneca, England, United Kingdom

Director of the Joint AZ-CRH Functional Genomics Centre (FGC) in Cambridge, UK - an exciting partnership with Cancer Research Horizons launched in 2019 and that has forged a world-leading centre of expertise in genetic screens, cancer models and CRISPR vector design for target discovery in cancer. Studying his degree in Biochemistry and Chemistry at Nottingham he moved to Astex Therapeutics to learn drug discovery, before returning to academia to complete his PhD and postdoc in molecular virology at the University of Leeds. He is passionate about applying cutting edge technologies to discover new medicines to change patients’ lives. Joining AstraZeneca in 2014 he has worked across target discovery building arrayed and pooled CRISPR capabilities, and now leads the FGC and its mission to discover new oncology targets.

Disclosure information not submitted.

Presentation(s):

• Application of Functional Genomic Technologies in Drug Discovery

  Monday, February 5, 2024
  3:00 PM – 5:00 PM EST

• The Joint AstraZeneca - Cancer Research Horizons Functional Genomics Centre (FGC): A pioneering partnership driving oncology target discovery using pooled CRISPR screening

  Monday, February 5, 2024
  3:00 PM – 3:30 PM EST